Amneal and bial announce u.s. licensing agreement for ongentys® (opicapone)

Bridgewater, n.j. & porto, portugal--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal”) and bial - portela & ca., s.a. (“bial”), today announced a licensing agreement where amneal will have exclusive rights to market and distribute ongentys® (opicapone) in the u.s. starting on december 18, 2023. amneal expects to begin distribution of ongentys® in early 2024. ongentys® is bial's proprietary once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inh.
AMRX Ratings Summary
AMRX Quant Ranking